- Nearly half of the 21M doses of COVID-19 vaccine developed by Johnson & Johnson (JNJ -0.7%) remains unused in the U.S., Reuters reported.
- According to the latest data from the U.S. Centers for Disease Control and Prevention (CDC), only ~11.2M doses of JNJ’s COVID-19 shot have been used in the country’s vaccine rollout.
- The single-dose shot suffered a safety-related setback in April when the U.S. authorities recommended a pause in its use citing extremely rare adverse events in the vaccine recipients.
- The CDC recommended the resumption of the rollout about 10 days later, but the demand has dipped over the six weeks the vaccine was in use.
- Compared to 3M doses leading up to the pause, less than 650K doses of JNJ’s shot have been administered up to the week ending May 25 making up ~5% of total vaccinations.
- The U.S. vaccine rollout has also lost momentum with the seven-day average of new doses administered reaching nearly 1M doses from a peak of 3M in April. JNJ will be among the 25M COVID-19 shots donated by the U.S. for global vaccination efforts.